Continue Reading Below
Shares ofNxStage Medical(NASDAQ: NXTM), a medical device company focused on renal care, rose by 11% as of 10:53 a.m. EDT on Thursday.
Image source: Getty Images.
The bullish move is traceable to the company's expectation-beatingthird-quarter results.
Revenue for the period came in at $92 million, which was up 6% over the same quarter last year. This figure surpassed the high end of management's previously announced guidance range and also exceeded Wall Street's expectation of roughly $2 million.
The stronger-than-expected top-line result led to success on the bottom line, too. The company's quarterly net loss was just $166,000, which was much better than the $1 million to $3 million loss it had forecasted. That produced a breakeven result on a per-share basis, exceeding analyst expectations of a $0.04 loss.
NxStage's founder and CEO, Jeffrey Burbank, was quite pleased with his company's performance and remained upbeat about its future prospects, saying, "We remain confident in our outlook for 2017 and beyond that includes targets for increasing the company's revenue growth and profitability. I believe we have a solid foundation, compelling growth drivers and an amazing technology pipeline."
Turning to the fourth quarter, management projects total revenue to come in right around $92 million, which should lead to a net loss between $1 million to $2 million, in line with what Wall Street was expecting. However, the company now believes that its full-year net loss will be between $4 million to $5 million, the midpoint of which is roughly 50% less than it had previously communicated. That's much lower than the $7.7 million loss that the Street anticipated.
Given the better-than-expected results and upbeat outlook, it is easy to understand why shareholders are feeling so bullish today.
A secret billion-dollar stock opportunity The world's biggest tech company forgot to show you something, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
Brian Feroldi has no position in any stocks mentioned.Like this article? Follow him onTwitter where he goes by the handle@Longtermmindsetor connect with him on LinkedIn to see more articles like this.
The Motley Fool owns shares of and recommends NxStage Medical. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.